{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:47:47Z","timestamp":1753357667359,"version":"3.40.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,8,15]],"date-time":"2012-08-15T00:00:00Z","timestamp":1344988800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1007\/s00115-012-3633-3","type":"journal-article","created":{"date-parts":[[2012,8,14]],"date-time":"2012-08-14T15:25:28Z","timestamp":1344957928000},"page":"584-589","source":"Crossref","is-referenced-by-count":2,"title":["R\u00fcckfallpr\u00e4vention bei Alkoholabh\u00e4ngigkeit: Acamprosat und Naltrexon als kombinierte pharmakologische Strategie","Relapse prevention in alcohol dependence: acamprosate and naltrexone as a combined pharmacological strategy"],"prefix":"10.1007","volume":"84","author":[{"given":"M.","family":"Gahr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"K\u00f6lle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Sch\u00f6nfeldt-Lecuona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,15]]},"reference":[{"key":"3633_CR1","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","volume":"29","author":"Anton","year":"2006","unstructured":"Anton R, O\u2019Malley S, Ciraulo D et al (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: randomized controlled trial. JAMA 29:2003\u20132017","journal-title":"JAMA"},{"key":"3633_CR2","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/01.ALC.0000078020.92938.0B","volume":"27","author":"Anton","year":"2003","unstructured":"Anton R, O\u2019Malley S, Ciraulo D et al (2003) Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study. Alcohol Clin Exp Res 27:1123\u20131131","journal-title":"Alcohol Clin Exp Res"},{"key":"3633_CR3","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1126\/science.2882604","volume":"236","author":"Cloninger","year":"1987","unstructured":"Cloninger C (1987) Neurogenetic adaptive mechanisms in alcoholism. Science 236:410\u2013416","journal-title":"Science"},{"key":"3633_CR4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.drugalcdep.2006.06.008","volume":"86","author":"Cohen","year":"2007","unstructured":"Cohen E, Feinn R, Arias A et al (2007) Alcohol treatment utilization: findings from the national survey on alcohol and related conditions. Drug Alcohol Depend 86:214\u2013221","journal-title":"Drug Alcohol Depend"},{"key":"3633_CR5","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0091-3057(92)90210-7","volume":"41","author":"Daoust","year":"1992","unstructured":"Daoust M, Legrand E, Gewiss M et al (1992) Acamprosate modulates synaptosomal GABA transmission in chronically alcoholised rats. Pharmacol Biochem Behav 41:669\u2013674","journal-title":"Pharmacol Biochem Behav"},{"key":"3633_CR6","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0022-3565(25)24051-4","volume":"271","author":"Emmerosn","year":"1994","unstructured":"Emmerosn P, Liu M, Woods J et al (1994) Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271:1630\u20131637","journal-title":"J Pharmacol Exp Ther"},{"key":"3633_CR7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/alcalc\/agl007","volume":"41","author":"Feeney","year":"2006","unstructured":"Feeney G, Connor J, Young R et al (2006) Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres\u2018 experience with pharmacotherapy. Alcohol Alcohol 41:321\u2013327","journal-title":"Alcohol Alcohol"},{"key":"3633_CR8","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","volume":"34","author":"Garbutt","year":"2010","unstructured":"Garbutt J, Kampov-Polevoy A, Gallop R et al (2010) Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res 34:1849\u20131857","journal-title":"Alcohol Clin Exp Res"},{"key":"3633_CR9","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1517\/13543784.2011.592139","volume":"20","author":"Hillemacher","year":"2011","unstructured":"Hillemacher T, Heberlein A, Muschler M et al (2011) Opioid modulators for alcohol dependence. Expert Opin Investig Drugs 20:1073\u20131086","journal-title":"Expert Opin Investig Drugs"},{"key":"3633_CR10","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1038\/sj.npp.1300790","volume":"30","author":"Ingman","year":"2005","unstructured":"Ingman K, Hagelberg N, Aalto S et al (2005) Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 30:2245\u20132253","journal-title":"Neuropsychopharmacology"},{"key":"3633_CR11","first-page":"281","volume":"23","author":"Johnson","year":"2003","unstructured":"Johnson B, O\u2019Malley S, Ciraulo D et al (2003) Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol 23:281\u2013293","journal-title":"J Clin Psychopharmacol"},{"key":"3633_CR12","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","volume":"298","author":"Johnson","year":"2007","unstructured":"Johnson B, Rosenthal N, Capece J et al (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641\u20131651","journal-title":"JAMA"},{"key":"3633_CR13","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/j.1530-0277.2011.01523.x","volume":"35","author":"Jorgensen","year":"2011","unstructured":"Jorgensen C, Pedersen B, Tonnesen H (2011) The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res 35:1749\u20131758","journal-title":"Alcohol Clin Exp Res"},{"key":"3633_CR14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","volume":"60","author":"Kiefer","year":"2003","unstructured":"Kiefer F, Jahn H, Tarnaske T et al (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism. Arch Gen Psychiatry 60:92\u201399","journal-title":"Arch Gen Psychiatry"},{"key":"3633_CR15","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/alcalc\/agh093","volume":"39","author":"Kiefer","year":"2004","unstructured":"Kiefer F, Wiedemann K (2004) Combined therapy: what does acamprosate and naltrexone combination tell us? Alcohol Alcohol 39:542\u2013547","journal-title":"Alcohol Alcohol"},{"key":"3633_CR16","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.ALC.0000057122.36127.C2","volume":"27","author":"Koob","year":"2003","unstructured":"Koob G (2003) Alcoholism: allostasis and beyond. Alcohol Clin Exp Res 27:232\u2013243","journal-title":"Alcohol Clin Exp Res"},{"key":"3633_CR17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1530-0277.1998.tb03611.x","volume":"22","author":"Koob","year":"1998","unstructured":"Koob G, Roberts A, Schulteis G et al (1998) Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res 22:3\u20139","journal-title":"Alcohol Clin Exp Res"},{"key":"3633_CR18","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/j.1530-0277.2011.01519.x","volume":"35","author":"Krampe","year":"2011","unstructured":"Krampe H, Spies C, Ehrenreich H (2011) Supervised disulfiram in the treatment of alcohol use disorder: a commentary. Alcohol Clin Exp Res 35:1732\u20131736","journal-title":"Alcohol Clin Exp Res"},{"key":"3633_CR19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jsat.2010.03.005","volume":"39","author":"Lee","year":"2010","unstructured":"Lee J, Grossmann E, Dirocco D et al (2010) Extended-release naltrexone for treatment of alcohol dependence in primary care. J Subst Abuse Treat 39:14\u201321","journal-title":"J Subst Abuse Treat"},{"key":"3633_CR20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/14740338.7.4.459","volume":"7","author":"Malcolm","year":"2008","unstructured":"Malcolm R, Olive M, Lechner W (2008) The safety of disufiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: guidance for clinical practice. Expert Opin Drug Saf 7:459\u2013472","journal-title":"Expert Opin Drug Saf"},{"key":"3633_CR21","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1530-0277.2008.00690.x","volume":"32","author":"Mann","year":"2008","unstructured":"Mann K, Kiefer F, Spanagel R et al (2008) Acamprosate: recent findings and future research directions. Alcohol Clin Exp Res 32:1105\u20131110","journal-title":"Alcohol Clin Exp Res"},{"key":"3633_CR22","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0376-8716(03)00134-0","volume":"71","author":"Mark","year":"2003","unstructured":"Mark T, Kranzler H, Song X (2003) Understanding US addiction physicians\u2018 low rate of naltrexone prescription. Drug Alcohol Depend 71:219\u2013228","journal-title":"Drug Alcohol Depend"},{"key":"3633_CR23","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/S0893-133X(02)00368-8","volume":"27","author":"Mason","year":"2002","unstructured":"Mason B, Goodman A, Dixon R et al (2002) A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 27:596\u2013606","journal-title":"Neuropsychopharmacology"},{"key":"3633_CR24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/187152710790966641","volume":"9","author":"Mason","year":"2010","unstructured":"Mason B, Heyser C (2010) Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets 9:23\u201332","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"3633_CR25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/14740330903512943","volume":"9","author":"Mason","year":"2010","unstructured":"Mason B, Heyser C (2010) The neurobiology, clinical efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence. Expert Opin Drug Saf 9:177\u2013188","journal-title":"Expert Opin Drug Saf"},{"key":"3633_CR26","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","volume":"56","author":"Mason","year":"1999","unstructured":"Mason B, Salvato F, Williams L et al (1999) A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 56:719\u2013724","journal-title":"Arch Gen Psychiatry"},{"key":"3633_CR27","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.1360-0443.2002.00019.x","volume":"9","author":"Miller","year":"2002","unstructured":"Miller W, Wilbourne P (2002) Mesa Grande: a methodological analysis of clinical trials of treatment for alcohol use disorders. Addiction 9:265\u2013277","journal-title":"Addiction"},{"key":"3633_CR28","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-2007-1016438","volume":"76","author":"Mutschler","year":"2008","unstructured":"Mutschler J, Diehl A, Kiefer F (2008) Pharmacology of disulfiram \u2013 an update. Fortschr Neurol Psychiatr 76:225\u2013241","journal-title":"Fortschr Neurol Psychiatr"},{"key":"3633_CR29","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1530-0277.1998.tb03871.x","volume":"22","author":"Naassila","year":"1998","unstructured":"Naassila M, Hammoumi S, Legrand E et al (1998) Mechanism of action of acamprosate. Part I. Characterization of spermidine-senstitive acamprosate binding site in rat brain. Alcohol Clin Exp Res 22:802\u2013809","journal-title":"Alcohol Clin Exp Res"},{"key":"3633_CR30","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1530-0277.2008.00843.x","volume":"33","author":"Pettinati","year":"2009","unstructured":"Pettinati H, Gastrfriend D, Dong Q et al (2009) Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol Clin Exp Res 33:350\u2013356","journal-title":"Alcohol Clin Exp Res"},{"key":"3633_CR31","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2004.03.004","volume":"47","author":"Pierrefiche","year":"2004","unstructured":"Pierrefiche O, Daoust M, Naassila M (2004) Biphasic effect of acamprosate on NMDA but not on GABA A receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network. Neuropharmacology 47:35\u201345","journal-title":"Neuropharmacology"},{"key":"3633_CR32","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1360-0443.2010.02899.x","volume":"105","author":"Rehm","year":"2010","unstructured":"Rehm J, Baliunas D, Borges G et al (2010) The relation between different dimensions of alcohol consumption and burden of disease: an overview. Addiction 105:817\u2013843","journal-title":"Addiction"},{"key":"3633_CR33","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0140-6736(09)60746-7","volume":"373","author":"Rehm","year":"2009","unstructured":"Rehm J, Mathers C, Popova S et al (2009) Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373:2223\u20132233","journal-title":"Lancet"},{"key":"3633_CR34","first-page":"CD004332","volume":"Rev","author":"R\u00f6sner","year":"2010","unstructured":"R\u00f6sner S, Hackl-Herrwerth A, Leucht S et al (2010) Acamprosate for alcohol dependence. Cochrane Database Syst Rev:CD004332","journal-title":"Cochrane Database Syst"},{"key":"3633_CR35","first-page":"CD001867","volume":"Rev","author":"R\u00f6sner","year":"2010","unstructured":"R\u00f6sner S, Hackl-Herrwerth A, Leucht S et al (2010) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev:CD001867","journal-title":"Cochrane Database Syst"},{"key":"3633_CR36","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1517\/13543784.2010.522990","volume":"19","author":"Soyka","year":"2010","unstructured":"Soyka M, R\u00f6sner S (2010) Nalmefene for treatment of alcohol dependence. Expert Opin Investig Drugs 19:1451\u20131459","journal-title":"Expert Opin Investig Drugs"},{"key":"3633_CR37","first-page":"CD001867","volume":"25","author":"Srisurapanont","year":"2005","unstructured":"Srisurapanont M, Jarusuraisin N (2005) Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 25:CD001867","journal-title":"Cochrane Database Syst Rev"},{"key":"3633_CR38","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cpr.2007.01.002","volume":"27","author":"Witkiewitz","year":"2007","unstructured":"Witkiewitz K, Marlatt G (2007) Modeling the complexity of post-treatment drinking: it\u2019s a rocky road to relapse. Clin Psychol Rev 27:724\u2013738","journal-title":"Clin Psychol Rev"},{"key":"3633_CR39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.drugalcdep.2011.05.001","volume":"118","author":"W\u00f6lwer","year":"2011","unstructured":"W\u00f6lwer W, Frommann N, J\u00e4nner M et al (2011) The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: a randomized controlled trial. Drug Alcohol Depend 118:417\u2013422","journal-title":"Drug Alcohol Depend"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-012-3633-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00115-012-3633-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-012-3633-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T21:53:42Z","timestamp":1743976422000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00115-012-3633-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,15]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["3633"],"URL":"https:\/\/doi.org\/10.1007\/s00115-012-3633-3","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"type":"print","value":"0028-2804"},{"type":"electronic","value":"1433-0407"}],"subject":[],"published":{"date-parts":[[2012,8,15]]}}}